TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02446132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study: NCT02065401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferitazole (magnesium hydroxide salt)
Description: Single oral dose of 2400 mg administered on Day 1
Study: NCT02581488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Santyl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product containing silver
Description: Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
Study: NCT01594918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2 or 20 mg/m2, IV, once every 21 days
Study: NCT01594918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg, SC, once every 21 days
Study: NCT02991469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Study: NCT04403555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin treatment
Study: NCT01075997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cell phone delivered tele-educational
Description: This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cell phone
Description: This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
Study: NCT01360788

Intervention type: DRUG
Intervention: Combination ipratropium/salbutamol or placebo (nebulization)
Description: The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.

Intervention type: DRUG
Intervention: Combination ipratropium/salbutamol or placebo (nebulization)
Description: The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
Study: NCT04143711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF1001
Description: Immunotherapy agent targeting NK cells.
Study: NCT02637310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N02RS1 1200mg
Description: 1200mg/day, Three times a day orally, 2 tablets once, 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1200mg/day, Three times a day orally, 2 tablets once, 7 days
Study: NCT01443741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education
Description: Specific program for FIT Therapy and specific program for traditional way

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education
Description: Specific program for FIT Therapy and specific program for traditional way
Study: NCT00536770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + gemcitabine + erlotinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol + gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcitriol + gemcitabine + erlotinib
Study: NCT04346407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5mg Cap
Description: 2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
Study: NCT03744403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
Study: NCT03319316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Combination of durvalumab + tremelimumab treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Combination of durvalumab + tremelimumab treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Combination of durvalumab + tremelimumab treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Combination of durvalumab + tremelimumab treatment
Study: NCT02532257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT03378245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral modification and education on pharmacologic treatments.
Description: Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
Study: NCT01726062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Incentives
Description: 1. Two hospital-based, face-to-face MI+ sessions~2. Two home-based MI+ sessions~3. Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional Care (CC)
Description: Participants in this arm will receive brochures and a brief information meeting in the NICU.
Study: NCT02532062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4,000 IU, oral, once a day for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin
Description: oral, once a day for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: oral, once a day for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral, once a day for one year
Study: NCT04498702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202 treatment
Description: A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
Study: NCT00621257

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol
Description: 8000 units/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: 8000 units/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol
Description: 8000 units/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ergocalciferol
Description: 8000 units/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 400 units per drop
Study: NCT05076604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cardioplegia Solution
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microplegic Solution No. 1
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.
Study: NCT05328453

Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal prenatal ultrasonographic evaluation.
Description: Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
Study: NCT02992860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56022473
Description: JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by \> 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow analyses and CBC with differential
Description: Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow cytometry analyses
Description: Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central biobanking
Description: Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Histopathology analysis
Description: A bone marrow biopsy is taken whenever it seems necessary to the investigator.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis
Description: The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum chemistry
Description: For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated CBC
Description: For CBC a minimum of 3 ml of peripheral blood have to be collected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
Study: NCT02360280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: sedative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: sedative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: sedative
Study: NCT02526160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burosumab
Description: solution for SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: burosumab
Description: solution for SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution for SC injection
Study: NCT03454087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral Dextrose Infusion
Description: A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Free Water Infusion
Description: An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
Study: NCT03519126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
Study: NCT00632125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 recombinant human erythropoietin alfa
Description: HX575 epoetin alfa i.v. will be administered according to the SmPC
Study: NCT04054817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix
Description: Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
Study: NCT01075919

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1 g DHA-rich fish oil taken daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 g olive oil taken daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1 g EPA-rich fish oil taken daily for 12 weeks
Study: NCT00626652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201 Injection
Description: single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
Study: NCT00030628

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Study: NCT01695382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: As per Arm description
Study: NCT03784313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin repair by axillary perforator flaps
Description: Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: skin repair by secondary wound healing
Description: Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
Study: NCT04575090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg daily.
Study: NCT01533402

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: therapist support
Description: Weekly therapist support without CBT-interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Internet-delivered cognitive behavioural therapy with therapist support
Study: NCT01240499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-At-Every-Size (HAES)
Description: 1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health-At-Every-Size (HAES)
Description: 1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study.
Study: NCT02869477

Intervention type: OTHER
Intervention: Data collection
Study: NCT00951158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid
Description: This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid
Description: Phase I Dose Escalation Study
Study: NCT00815997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: PCI will be performed via the radial artery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: PCI will be performed via the radial artery.
Study: NCT03633253

Intervention type: OTHER
Intervention: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Description: First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.

Intervention type: OTHER
Intervention: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Description: First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.